Avalo Therapeutics, Inc. Enters $200,000,000 At-The-Market Offering Program and Terminates Prior Agreement

On November 5, 2026, Avalo Therapeutics entered into an agreement with Jefferies for an at-the-market offering program. Avalo may sell shares of its common stock from time to time at its sole discretion; the provided article text does not specify an offering amount or indicate that shares have been sold.